Results 11 to 20 of about 89,075 (280)

Cholangiocarcinoma [PDF]

Pathologica, 2021
Cholangiocarcinoma (CCA) is a highly lethal adenocarcinoma of the hepatobiliary system, which can be classified as intrahepatic, perihilar and distal.
P. Brindley, Melinda Bachini, S. Ilyas, Shahid A. Khan, A. Loukas, A. Sirica, B. Teh, S. Wongkham, Gregory J. Gores   +8 more
semanticscholar   +8 more sources

Cholangiocarcinoma

Neoplasms of the Biliary Tract, 2020
Cholangiocarcinomas are tumors that arise from the biliary tract, a part of the digestive system. Although rare, these types of tumors have shown a steady increasing in prevalence and now account for 3% of all gastrointestinal (GI) cancers. These cancers
Jae Hoon Lim, Kee-Taek Jang, Jung Hoon Kim   +2 more
semanticscholar   +2 more sources

Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles [PDF]

PeerJ, 2022
Background Cholangiocarcinoma (CCA) is a malignancy of the cholangiocytes. One of the major issues regarding treatment for CCA patients is the development of chemotherapeutic resistance.
Sirinya Sitthirak, Manida Suksawat, Jutarop Phetcharaburanin, Arporn Wangwiwatsin, Poramate Klanrit, Nisana Namwat, Narong Khuntikeo, Attapol Titapun, Apiwat Jarearnrat, Sakkarn Sangkhamanon, Watcharin Loilome   +10 more
doaj   +2 more sources

Metabolomic analyses uncover an inhibitory effect of niclosamide on mitochondrial membrane potential in cholangiocarcinoma cells [PDF]

PeerJ, 2023
Background Niclosamide is an oral anthelminthic drug that has been used for treating tapeworm infections. Its mechanism involves the disturbance of mitochondrial membrane potential that in turn inhibits oxidative phosphorylation leading to ATP depletion.
Thanaporn Kulthawatsiri, Yingpinyapat Kittirat, Jutarop Phetcharaburanin, Jittima Tomacha, Bundit Promraksa, Arporn Wangwiwatsin, Poramate Klanrit, Attapol Titapun, Watcharin Loilome, Nisana Namwat   +9 more
doaj   +2 more sources

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.

New England Journal of Medicine, 2023
BACKGROUND Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis.
L. Goyal, F. Meric-Bernstam, A. Hollebecque, J. Valle, C. Morizane, T. Karasic, T. Abrams, J. Furuse, R. Kelley, P. Cassier, H. Klümpen, H. Chang, Li-Tzong Chen, J. Tabernero, Do-Youn Oh, A. Mahipal, M. Moehler, E. Mitchell, Y. Komatsu, Kunihiro Masuda, Daniel H Ahn, R. Epstein, A. Halim, Yao Fu, T. Salimi, V. Wacheck, Yaohua He, Mei Liu, K. Benhadji, J. Bridgewater   +29 more
semanticscholar   +1 more source

1H NMR fecal metabolic phenotyping of periductal fibrosis- and cholangiocarcinoma-specific metabotypes defining perturbation in gut microbial-host co-metabolism [PDF]

PeerJ, 2023
Background The liver fluke Opisthorchis viverrini (OV), which subsequently inhabits the biliary system and results in periductal fibrosis (PDF), is one of the primarily causes of cholangiocarcinoma (CCA), a bile duct cancer with an exceptionally high ...
Rujikorn Treeriya, Phuc N. Ho, Attapol Titapun, Poramate Klanrit, Manida Suksawat, Thanaporn Kulthawatsiri, Suphasarang Sirirattanakul, Watcharin Loilome, Nisana Namwat, Arporn Wangwiwatsin, Nittaya Chamadol, Narong Khuntikeo, Jutarop Phetcharaburanin   +12 more
doaj   +2 more sources

Cholangiocarcinoma [PDF]

The Lancet, 2014
Cholangiocarcinoma represents a diverse group of epithelial cancers united by late diagnosis and poor outcomes. Specific diagnostic and therapeutic approaches are undertaken for cholangiocarcinomas of different anatomical locations (intrahepatic, perihilar, and distal).
Razumilava, Nataliya, Gores, Gregory J
openaire   +3 more sources

Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians

Ca, 2022
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients are eligible for resection, which is considered the only potentially ...
D. Moris, M. Palta, Charles Kim, P. Allen, M. Morse, M. Lidsky   +5 more
semanticscholar   +1 more source

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

JAMA Oncology, 2021
Key Points Question Does ivosidenib treatment improve overall survival outcomes vs placebo among patients with chemotherapy-refractory cholangiocarcinoma with IDH1 mutation?
A. Zhu, T. Macarulla, M. Javle, R. Kelley, S. Lubner, J. Adeva, J. Cleary, D. Catenacci, M. Borad, J. Bridgewater, W. Harris, A. Murphy, D. Oh, J. Whisenant, M. Lowery, L. Goyal, R. Shroff, A. El-Khoueiry, Christina X. Chamberlain, E. Aguado-Fraile, S. Choe, Bin Wu, Hua Liu, C. Gliser, S. Pandya, J. Valle, G. Abou-Alfa   +26 more
semanticscholar   +1 more source

Accuracy of a new rapid diagnostic test for urinary antigen detection and assessment of drug treatment in opisthorchiasis

Infectious Diseases of Poverty, 2023
Background Screening for opisthorchiasis, a parasitic worm infection affecting many millions of people in Southeast Asia, has traditionally relied on faecal egg examination such as the formalin-ethyl acetate concentration technique (FECT) and Kato-Katz ...
Chanika Worasith, Jiraporn Sithithaworn, Phattharaphon Wongphutorn, Chutima Homwong, Kanoknan Khongsukwiwat, Anchalee Techasen, Kulthida Y. Kopolrat, Watcharin Loilome, Nisana Namwat, Bandit Thinkamrop, Chaiwat Tawarungruang, Attapol Titapun, Thewarach Laha, Ross H. Andrews, Simon D. Taylor-Robinson, Paiboon Sithithaworn   +15 more
doaj   +1 more source